



Company Announcement

Phosphagenics Appoints Three New Directors

13 April 2015, Melbourne: Australian drug delivery company, Phosphagenics Limited (ASX: POH; OTCQX: PPGNY), announces that it has appointed three new directors to The Board. The new directors include Dr Greg Collier, Mr Peter Lankau and the Company's recently appointed CEO, Dr Ross Murdoch.

Dr Greg Collier is currently the CEO of ASX listed company Invion Ltd, and has more than 20 years' experience spanning operational, clinical and scientific aspects of pharmaceutical research, development and commercialisation. He has executed multiple commercial transactions and has successfully taken a drug from discovery through to regulatory approval.

Dr Collier steered ChemGenex Pharmaceuticals from a research-based company with a market capitalisation of \$10M to a company that completed clinical trials and submitted regulatory dossiers to the FDA and EMA. In 2011, ChemGenex was sold to Cephalon for \$230M.

During Dr Collier's distinguished academic career, before entering the commercial world, he published over 150 peer reviewed articles, as well as having senior authorship on 33 patents. Dr Collier was the inaugural Alfred Deakin Professor at Deakin University and also held positions at the University of Melbourne, Monash University and the University of Toronto. In 2010, Dr Collier was awarded the Roche Award of Excellence for his contribution to the biotechnology industry.

Mr Peter Lankau served as the Chief Executive Officer (CEO) of Endo Pharmaceuticals Inc. from 2005 to 2008 and as Chief Operating Officer from 2003 to 2005. From 2000 to 2003, he served as Senior Vice President of U.S. Business. Endo is a US based Pharmaceutical Company which has over recent years been one of the largest companies commercialising drugs in the pain industry. Endo's product range includes Lidoderm (lidocaine), Percodan (oxycodone with aspirin), Opana (oxymorphone) and Voltaren Gel (diclofenac) licensed from Novartis.

In recent years Mr Lankau has served on multiple company boards including Nautilus Neuroscience Inc. which in 2013 sold the assets of that company, including its oral diclofenac product to Depomed Inc. for over \$50 million.

Dr Ross Murdoch has over 25 years' experience in the global Healthcare, Pharmaceutical and Biotech industries and has held senior and executive positions with global Pharmaceutical companies such as GlaxoSmithKline, Astra Zeneca and Shire Pharmaceuticals where he built significant specialised business divisions. He has also worked for much smaller companies such as Prana Biotechnology where he was COO. His appointment to the board was a natural transition, having commenced as CEO of Phosphagenics in January 2015.

Phosphagenics Limited

ACN 056 482 403 ABN 32 056 482 403

11 Duerdin Street, Clayton VIC 3168

PO Box 1415, Clayton South MDC VIC 3169 Australia

Tel: +61 (0)3 9565 1119 Fax: +61 (0)3 9565 1151

www.phosphagenics.com Email: info@phosphagenics.com

Lawrence Gozlan chairman of Phosphagenics said, “I am delighted to welcome the newly appointed directors to Phosphagenics’ board. The skill set of these directors will be invaluable in optimising commercial outcomes for Phosphagenics’ TPM platform technology. They are highly respected by their peers and their willingness to serve on the board is a strong endorsement of our technology.”

ENDS

Enquiries

David Segal
Phosphagenics Limited
+61 3 9565 1119

About Phosphagenics

Phosphagenics Limited is a drug delivery company that is commercialising various products within the pharmaceutical, cosmetics and animal health sectors, using its proprietary drug delivery system called TPM[®] (Targeted Penetration Matrix). TPM[®] is a patient friendly and cost effective system, based on Vitamin E, that enhances the topical or transdermal delivery of active molecules. The lead products advancing through clinical trials are oxymorphone and oxycodone patches for the relief of chronic pain.

Phosphagenics' shares are listed on the Australian Securities Exchange (POH) and its ADR – Level 1 program in the US is with The Bank of New York Mellon (PPGNY).

www.phosphagenics.com
www.bioelixia.com